Study: One-third of older adults with cognitive disorders take risky CNS drugs
A new analysis finds that many seniors with dementia or other cognitive conditions are prescribed medications that can worsen their health and lead to emergency visits.
A report covered by Medical Xpress highlights a concerning pattern in geriatric care: roughly one in three adults aged 65 and older who have cognitive disorders such as dementia are taking prescription medications that could do them harm. The drugs in question act on the central nervous system and include treatments commonly used for anxiety, sleep difficulties, and psychosis.
Because older adults with cognitive impairments are especially vulnerable to the side effects of these medications, the consequences can be serious. The source notes that such prescriptions are associated with increased emergency department visits and more frequent adverse events, though the full scope of outcomes is not detailed in the excerpt.
The findings underscore a tension between managing behavioral symptoms and protecting an already fragile patient population. While the source does not compare this pattern to younger patients or those without cognitive disorders, it makes clear that the scale of risky prescribing is substantial among this group.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.